Not only does drug delivery provide improved efficacy and differentiable products, it also offers the most cost-efficient drug development and the highest return on investment in the industry, according to Jerry Treppel of Dillon, Read, speaking at a conference on the generic drug and drug delivery industries in New York, USA, last month sponsored by his firm.
The concept of drug delivery has passed through many stages, he said, from being merely a "better idea" to being a "better idea that really works." While brand-name drug companies today are facing severe generic competition and consolidation, the drug delivery industry is now seeing the development of full-line vertically-integrated drug delivery companies such as Ivax and Elan, the development of proprietary products including New Chemical Entities and biotechnology companies becoming major customers.
Mr Treppel said the drug delivery industry is also benefiting from the failure of many brand-name companies which had gone into drug development on a specific basis rather than creating a broader technological expertise, as well as the rising pressure for companies to market controlled-release products and the trend for outsourcing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze